|
4basebio PLC on Tuesday announced the promotion of Business Development Vice President Christine Wolosin to chief commercial officer, following the appointment of Amy Walker to chief executive last month. ‘Christine will work closely with Amy to execute 4basebio‘s accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers seek alternatives to plasmid DNA,’ the Cambridge, England-based life sciences company said. 4basebio said Wolosin, who joined in September last year as vice president of business development, will lead its global commercial strategy, business development initiatives, and customer engagement as it scales its synthetic DNA platform. ‘4basebio’s proprietary synthetic DNA platform addresses critical limitations of traditional plasmid-based systems, offering biopharma partners key speed, purity and scalability advantages,’ the new CCO commented. ‘I have enjoyed working with the talented team at 4basebio to accelerate partnerships with innovators in gene therapy, mRNA therapeutics, and next-generation vaccines. ‘The market opportunity is substantial, and we are uniquely positioned to capture it.’ The firm noted that Wolosin has over 25 years of experience in life sciences and ‘a proven track record of building and scaling go-to-market capabilities in the cell and gene therapy space’, including her role as vice president of business development at Emmes before joining 4basebio. She has also held senior roles at ‘leading’ organisations like Thermo Fisher Scientific, ‘where she led the go-to-market launches for a number of advanced therapy offerings, including [Thermo Fisher’s] viral vector manufacturing expansion at its flagship Plainville, Massachusetts facility.’ ‘4basebio is moving into an accelerated commercial phase as the company scales operations and builds partnerships across RNA, cell and gene therapy and vaccine development,’ commented CEO Amy Walker. ‘Since joining 4basebio, Christine has demonstrated an ability to build strategic relationships within the nucleic acid manufacturing space and a deep understanding of customer needs in the advanced therapy sector. ‘Her leadership and experience will be instrumental as we work to establish 4basebio as the partner of choice for companies developing next-generation therapeutics and vaccines.’ 4basebio shares closed down 5.8% at 508.80 pence on Friday in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
